PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
43 hedge funds and large institutions have $3.83M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
10% more funds holding
Funds holding: 39 → 43 (+4)
38% less capital invested
Capital invested by funds: $6.13M → $3.83M (-$2.3M)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.4K |
| 2 |
LPL Financial
San Diego,
California
|
+$28.1K |
| 3 |
GW
GW & Wade
Wellesley,
Massachusetts
|
+$23.7K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$280K |
| 2 |
Millennium Management
New York
|
-$177K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$59.8K |
| 4 |
CC
Cannell & Co
New York
|
-$52K |
| 5 |
Renaissance Technologies
New York
|
-$9K |
PVCT Hedge Fund Activity: Q4 2015 in Review
43 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2015, worth a combined $3.83M — down 38% from $6.13M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PVCT positions and 4 closed out — a net gain of 5 holders — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $48.4K. The largest seller was Goldman Sachs, cutting an estimated $280K.
- 43 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2015, up from 39 in Q3 2015.
- Funds reported $3.83M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2015, down 38% quarter-over-quarter.
- 9 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2015 and 4 closed out, a net change of +5 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q4 2015 was Vanguard Group, an estimated $48.4K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2015 was Goldman Sachs, an estimated $280K sold.
Based on aggregated 13F filings for Q4 2015.